Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies

Leica Biosystems and Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, today announced an agreement to collaborate on the development and commercialization of a companion diagnostic test using the Leica BOND system, paired with one of Synthon Biopharmaceutical’s antibody-drug conjugates (ADCs), to enhance the treatment of solid tumors.

“We are pleased to be working with Synthon Biopharmaceuticals on cancer therapies with the Leica BOND platform,” added Matthias Weber, President of Leica Biosystems, MD. “This partnership with Synthon is the next example of our commitment to provide unique tests to support the management of cancer patients. The ease of use and high staining quality of our BOND systems makes them ideal platforms on which to deploy these very informative tests”.

Dr. Leon Hooftman, Chief Medical Officer at Synthon, comments: “Synthon is committed to develop a best-in-class ADC. This collaboration with Leica Biosystems will support us in delivering on that ambition.”